Table 1.
Patient characteristics at primary diagnosis and prior treatment
| Parameters | No. of patients | Proportion of patients (%) |
|---|---|---|
| Age at primary diagnosis | ||
| Median(y) | 45 | – |
| Range(y) | 31–67 | – |
| ≤50 y | 36 | 70.6 |
| >50y | 15 | 29.4 |
| T stage at primary diagnosis | ||
| T1 | 19 | 37.3 |
| T2 | 29 | 56.9 |
| T3 | 3 | 5.9 |
| T4 | 0 | 0 |
| Primary N stage | ||
| N0 | 21 | 41.2 |
| N1 | 20 | 39.2 |
| N2 | 5 | 9.8 |
| N3 | 5 | 9.8 |
| Primary stage | ||
| I | 9 | 17.6 |
| II | 30 | 58.8 |
| III | 12 | 23.5 |
| ER/PR status at primary diagnosis | ||
| Negative | 16 | 31.4 |
| Positive | 33 | 64.7 |
| Not available | 2 | 3.9 |
| HER-2/neu status at primary diagnosis | ||
| Negative | 38 | 74.5 |
| Positive a | 6 | 11.8 |
| Not available | 7 | 13.7 |
| Prior surgery | ||
| Modified radical mastectomy | 42 | 82.4 |
| Radical mastectomy | 9 | 17.6 |
| Prior chemotherapy | ||
| Yes | 48 | 94.1 |
| No | 3 | 5.9 |
| Prior Hormone therapy | ||
| TAM | 27 | 52.9 |
| AI | 5 | 9.8 |
| No | 19 | 37.3 |
a: Patients were considered to have HER-2/neu positive disease if primary tumor was positive for HER-2 by immunohistochemistry (+++) or by fluorescent in-situ hybridization